NanO 2NanO2PaclitaxelGlioblastoma MultiformeTNBCTriple-negative breast cancerDOD GrantBALB/c mice
…oxygenation strategies remain limited for clinical translation. NanO 2 (NuvOx Pharma), a novel perfluorocarbon-based oxygen therapeuti…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 481–540 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
SGLT2 inhibitors7Tebentafusp7ethambutol7Albumin7mSTAR13027Bimekizumab7LA7RPV7Alirocumab7Ixekizumab7TXA7pyrazinamide7Antidepressant7B7-H37Botox7Ibrutinib7Apalutamide7Heroin7MRA7Palbociclib7TGF-β17bDMARD7Enfortumab vedotin7fluoroquinolones7sintilimab7DES7IL-107Neostigmine7bDMARDs7methamphetamine7posaconazole7MDMA7Tetracycline7Labetalol7Piperacillin-tazobactam7Acyclovir7DOACs7IL-67Monoclonal antibodies7NSAID7TGF-β7DORAvirine7Nimodipine7bronchodilator7leflunomide7melphalan7metoprolol70.2% ropivacaine7Antihypertensives7NSAIDs7angiotensin receptor blockers7anticentromere7bortezomib7clindamycin7codeine7dipeptidyl peptidase-4 inhibitors7esomeprazole7flucloxacillin7Glucagon-like peptide-1 (GLP-1) receptor agonists7Janus kinase inhibitors7
Articles mentioning drugs
10,506 articles · page 86 of 876APMV-4IpilimumabaCTLA-4CTLA-4Icahn School of Medicine at Mount SinaiCRC
… tumors and tumor draining lymph nodes to unveil the effects of APMV-4 ISV on host immune responses. Ex vivo splenocyte stimulation wa…
OdronextamabREGN5837odronextamab-mediatednon-Hodgkin lymphomaDLBCLfollicular lymphomadiffuse large B cell lymphoma
…ent strategies are required to achieve durable tumor rejection. Odronextamab, a CD20xCD3 bispecific antibody, has been approved in the EU fo…
pramlintideEwing sarcomatype II DiabetesEWSprostate carcinoma
…ing tumor acidity and reshaping the metabolic microenvironment, pramlintide may enhance immune cell trafficking and function, supporting it…
ipilimumabnivolumabICIimmune checkpoint inhibitorsmelanomaBrown University Health
…lick AC, Jiang J, Avila A, … Margolin K. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. The New England Journal of…
TNG260pembrolizumabTNG260-inducedNSCLCNon-small cell lung cancerNCT05887492immune checkpoint-based therapies
…tial treatment strategy for patients with STK11-mutated tumors. TNG260 in combination with pembrolizumab is currently being evaluated …
Trastuzumab emtansinetrastuzumabCBD-IL-7T-DM1PMPCCBD-IL-12T-DM1Imperial College LondonHigh-grade serous ovarian carcinoma (HGSOC)University of Alabama at Birminghamepithelial ovarian cancer
…ulatory cytokines, intensifying the anti-tumor response.Methods Trastuzumab emtansine (T-DM1, KADCYLA) served as the lead ADC. To increase the drug p…
cisplatincarboplatincisplatin-inducedcisplatin-treatedPEG-ADANSCLCnon-small cell lung cancer
…ti-PD-1 or anti-PD-L1 antibodies) plus concurrent chemotherapy (cisplatin or carboplatin) is now part of the standard of care for non-sma…
OxPhosNDUFS4NDUFA7gastric cancerMC38 murine colorectal cancer
…the metabolic and functional suppression observed with existing OxPhos inhibitors. In vivo, NDUFA7 knockdown MC38 tumors show signific…
Daiad-2/15Daiad TM-2/15Neo-2/15IL-2IL-15vascular leak syndromecytokine release syndrome
…nt on the same cell.Conclusions Together, our data suggest that Daiad-2/15 could potentiate the systemic delivery of a highly potent immun…
cGASΔN-LNPscGASΔN-LNPαPD-L1 monoclonal antibodyGFP-LNPsGFP-LNPendometrial cancerWCG Institutional Review Board
…nto microfluidic devices, and treated with GFP-LNPs (10 µg/ml), cGASΔN-LNPs (1 and 10 µg/ml), or αPD-L1 monoclonal antibody (300 µg/ml). GF…
177Lu-A2DM177Lu-RPT177Lu169Tm-A2DM225Ac-A2DM225Ac-RPTA2DMpancreatic cancersCity of Hope Institutional Animal Care and Use CommitteeRPT
…t 48 hr. For low-dose RPT, mice were administered 225Ac-A2DM or 177Lu-A2DM, and tumors collected at days 4, 7 and/or 14. Tissues were form…